US Pharma MarketingThe post Ocugen begins Phase III trial of OCU410 gene therapy for GA appeared first on Clinical Trials Arena.
Ocugen begins Phase III trial of OCU410 gene therapy for GA
Ocugen has commenced its global Phase III ArMaDa3 trial of OCU410, an investigational gene therapy for GA secondary to dAMD, with the dosing of the first patient. The Phase III study randomises GA patients in 2:1 ratio to receive either OCU410 or no treatment. OCU410 is designed to be administered as a single subretinal injection. Credit: Hryshchyshen Serhii / Shutterstock.com. Ocugen has initiated its global Phase III ArMaDa3 trial of OCU410, an investigational gene therapy for geographic atrophy (GA) secondary to dry age-related macular degeneration (dAMD), with the dosing of the first patient. The randomised, controlled, multi-centre study is being…
Ocugen has commenced its global Phase III ArMaDa3 trial of OCU410, an investigational gene therapy for GA secondary to dAMD, with the dosing of the first patient.
Source: Clinical Trials Arena